| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 09/26/2001 | EP1135682A1 Nanoparticles with polymer shells |
| 09/26/2001 | EP1135481A1 New oligomeric conjugates liable to transfer biological molecules into cells |
| 09/26/2001 | EP1135463A2 Lymphoid tissue-specific cell production from hematopoietic progenitor cells in three-dimensional devices |
| 09/26/2001 | EP1135439A1 Poly(alpha-1,4-d-glucan) and thermoplastic polymer mixtures containing the same |
| 09/26/2001 | EP1135418A1 Biopolymer salts with low endotoxin levels, biopolymer compositions thereof and methods of making the same |
| 09/26/2001 | EP1135416A2 Tumor specific human monoclonal antibodies and methods of use |
| 09/26/2001 | EP1135410A2 Antennapedia homeodomain helix 3 derived translocation vectors |
| 09/26/2001 | EP1135397A1 Method for preparation of disodium pamidronate |
| 09/26/2001 | EP1135373A1 Crystalline form of an octahydro-benzo(f)quinolin-3-one derivative |
| 09/26/2001 | EP1135359A1 Derivatives of (-)-venlafaxine and methods of preparing and using the same |
| 09/26/2001 | EP1135358A1 Derivatives of (+)-venlafaxine and methods of preparing and using the same |
| 09/26/2001 | EP1135178A1 Polymeric coatings with controlled delivery active agents |
| 09/26/2001 | EP1135173A1 A medicinal aerosol formulation |
| 09/26/2001 | EP1135169A1 Pharmaceutical composition comprising an anti-cancer agent and at least a peptide |
| 09/26/2001 | EP1135168A1 Peptides carrying substances across the blood brain barrier |
| 09/26/2001 | EP1135167A2 Methods and formulations for reducing circulating antibodies |
| 09/26/2001 | EP1135166A1 Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 09/26/2001 | EP1135165A1 Stent having drug crystals thereon |
| 09/26/2001 | EP1135164A1 Method for the treatment of inflammation |
| 09/26/2001 | EP1135163A1 Topical compositions comprising ascomycins |
| 09/26/2001 | EP1135162A2 Ordered molecular presentation of antigens, method of preparation and use |
| 09/26/2001 | EP1135160A2 Boron neutron capture therapy using pre-targeting methods |
| 09/26/2001 | EP1135152A1 A pharmaceutical composition comprising cyclosporin in a lipid carrier |
| 09/26/2001 | EP1135150A1 Self-emulsifying compositions for drugs poorly soluble in water |
| 09/26/2001 | EP1135147A2 Method for producing medicaments from plant extracts, in a solid form of administration |
| 09/26/2001 | EP1135143A1 Immunomodulatory methods using carbohydrate antigens |
| 09/26/2001 | EP1135139A1 Micronized eplerenone compositions |
| 09/26/2001 | EP1135137A1 Copolymer compositions for treating viral infections |
| 09/26/2001 | EP1135127A1 New pharmaceutical composition and the process for its preparation |
| 09/26/2001 | EP1135125A1 Controlled-release dosage forms comprising zolpidem or a salt thereof |
| 09/26/2001 | EP1135120A2 Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents |
| 09/26/2001 | EP1135118A1 Dispersible compositions containing l-dopa ethyl ester |
| 09/26/2001 | EP1135112A1 An oral formulation for gastrointestinal drug delivery |
| 09/26/2001 | EP1135111A2 Autoadhesive oral transmucosal delivery dosage form |
| 09/26/2001 | EP1135110A1 Preparation of dry compositions soluble in the presence of water and avoiding maillard reaction in dry state and uses |
| 09/26/2001 | EP1135106A1 Sustained release matrix systems for highly soluble drugs |
| 09/26/2001 | EP1135105A2 Method for administering agents to the central nervous system |
| 09/26/2001 | EP1003499B1 Diclofenac solution for topical application |
| 09/26/2001 | EP0988033B1 Use of dichlorobenzyl alcohol for preparing a preparation for topical treatment of inflammation |
| 09/26/2001 | EP0888772B1 Sustained-release metal valproate tablets |
| 09/26/2001 | EP0839026B1 Polyether block copolymer micellar compositions for targeting biological agents |
| 09/26/2001 | EP0825860B1 Use of a composition comprising amoxycillin and clavulanic acid for the manufacture of a medicament for the treatment of bacterial infections in paediatric patients |
| 09/26/2001 | EP0732914B1 Sulfated polyvinyl alcohol polymers to stabilize pharmaceutical drug compounds |
| 09/26/2001 | EP0723436B1 Multiple unit tableted dosage form i |
| 09/26/2001 | EP0706383B1 Compositions for inhalation |
| 09/26/2001 | EP0528991B1 Detectably labelled marker component comprising a fluorophore moiety , fluorescent probe comprising the marker component and uses thereof. |
| 09/26/2001 | CN1314900A Particle-formijng compositions containing fused pyrrolocarbazoles |
| 09/26/2001 | CN1314808A Foaming oil preparation and its use |
| 09/26/2001 | CN1314804A Improved stability for injection solutions |
| 09/26/2001 | CN1314449A Method for extracting plant solid slag to obtain anti-oxidant through self anaerobic fermentation and produced extract |
| 09/26/2001 | CN1314189A Preparation of high molecular gel stick agent |
| 09/26/2001 | CN1071760C N-terminally chemically modified protein composition and methods |
| 09/26/2001 | CN1071579C Process for preparing anti-body conjugates for treamtent of tumor disease |
| 09/26/2001 | CN1071570C Extended release, film-coated table of astemizole and pseudoephedrine |
| 09/25/2001 | US6294697 Discrete-length polyethylene glycols |
| 09/25/2001 | US6294548 Mixture of indazole, preservative and benzyl alcohol anti-emetic, particularly in the treatment of cytotoxic agent induced emesis, in u.s. |
| 09/25/2001 | US6294340 Method of binding material to the β-amyloid peptide |
| 09/25/2001 | US6294321 Simple method by contacting sample with beta-(1-3)-glucan binding agent to form complexes, then detecting complexes as indication of infection |
| 09/25/2001 | US6294199 The dosage is provided by a bilayer tablet. |
| 09/25/2001 | US6294197 Known to be effective in the treatment of congestive heart failure and reducing blood pressure. |
| 09/25/2001 | US6294196 Pharmaceutical composition containing diphosphonic acid or salt thereof |
| 09/25/2001 | US6294194 Improving mass transfer rates, removing soluble compositions from materials. such as capsule mold lubricants, residual solvents, and contaminants from chemical and pharmaceutical containers and preparations, repeatedly modulating the |
| 09/25/2001 | US6294173 Methods for treating a tumor containing fibrin using a fibrin specific monoclonal antibody and compositions used therein |
| 09/25/2001 | US6294172 Monoclonal antibodies with specificity for membrane-associated antigens |
| 09/25/2001 | US6294170 Composition and method for treating inflammatory diseases |
| 09/25/2001 | US6294153 Aerosol pharmaceutical formulation for pulmonary and nasal delivery |
| 09/25/2001 | US6294151 Diagnosing the infection with urease-generating bacteria, particularly helicobacter pylori. |
| 09/24/2001 | CA2341618A1 Proanthocyanidin-containing composition |
| 09/23/2001 | CA2341926A1 Oral formulations of medicaments |
| 09/20/2001 | WO2001069259A1 Method for detecting guanylyl cyclase and use thereof for diagnosing metastatic colorectal tumours |
| 09/20/2001 | WO2001068767A1 Dispersion comprising a non-ionic emulsifier |
| 09/20/2001 | WO2001068722A1 Hydrogel biomedical articles |
| 09/20/2001 | WO2001068721A1 Tissue bulking and coating compositions |
| 09/20/2001 | WO2001068708A2 Human and humanized fap-alpha-specific antibodies |
| 09/20/2001 | WO2001068679A2 Peptides targeting specifically tumor-derived endothelial cells |
| 09/20/2001 | WO2001068145A2 Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use |
| 09/20/2001 | WO2001068144A2 Biodegradable immunomodulatory formulations and methods for use thereof |
| 09/20/2001 | WO2001068143A2 Immunomodulatory formulations and methods for use thereof |
| 09/20/2001 | WO2001068142A1 Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same |
| 09/20/2001 | WO2001068141A2 Dispersions of polypeptide conjugates |
| 09/20/2001 | WO2001068140A2 Opioid formulations |
| 09/20/2001 | WO2001068139A1 Formulation solubilizing water-insoluble agents and preparation method thereof |
| 09/20/2001 | WO2001068138A2 Intradermal-penetration agents for topical local anesthetic administration |
| 09/20/2001 | WO2001068129A2 Adjuvant for vaccines |
| 09/20/2001 | WO2001068122A2 A method for reversing the immunosuppressive effects of the melanoma inhibitory activity 'mia' |
| 09/20/2001 | WO2001068120A2 Uses of bombesin receptor 3 |
| 09/20/2001 | WO2001068102A2 Nystatin formulation having reduced toxicity |
| 09/20/2001 | WO2001068099A1 Modulation of cardiovascular injury |
| 09/20/2001 | WO2001068092A2 Glycogen phosphorylase inhibitor |
| 09/20/2001 | WO2001068081A1 Agent for treating illnesses of the tracheobronchial tract, especially chronic obstructive pulmonary disease (copd) |
| 09/20/2001 | WO2001068079A2 Viscoelastics for use in middle ear surgery |
| 09/20/2001 | WO2001068075A2 Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals |
| 09/20/2001 | WO2001068060A2 Stabilised oversaturated transdermal therapeutical matrix systems |
| 09/20/2001 | WO2001068058A1 Multilayer pharmaceutical product for release in the colon |
| 09/20/2001 | WO2001068055A1 Pharmaceutical compositions of glycogen phosphorylase inhibitors |
| 09/20/2001 | WO2001068054A1 Process for the preparation of accelerated release formulations using compressed fluids |
| 09/20/2001 | WO2001068038A2 System for the controlled delivery of an active material to a dental site |
| 09/20/2001 | WO2001067896A2 Method of producing oily suspensions of water-soluble vitamins |
| 09/20/2001 | WO2001067894A1 Fading inhibitors |
| 09/20/2001 | WO2001067889A1 Diabetic nutritionals |